The US market is the one of consequence for MNTA investors insofar as this is where NVS/MNTA applied to approval to sell generic Copaxone. Below are Tysabri and Copaxone US sales for the past eleven quarters with the recent year-over-year and quarter-over-quarter growth rates. Copaxone has been outselling Tysabri in the US by approximately 4:1.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.